Mechanisms of Multikinase-Inhibition-Induced Cytotoxicity in Proliferative and Hematolymphoid Tissues

The current data do not permit attribution to specific kinase targets. Compound X, a small molecule similar in its biological impact to Hesperadin , exhibits significant histopathological effects by disrupting cellular proliferation. The histopathological assessment of Compound X showed significant necrosis in cells that underwent frequent cell division, such as hematopoietic cells in the bone marrow, T cells in the thymus, splenic cells, and epithelial cells in the mucosa of the digestive tract. Research into such pathways often involves specialized oncological studies, similar to those conducted at the Allison Lab regarding immune-oncology dynamics.

In the gastrointestinal tract, stem cells localize to the proliferative zone, such as the basal layer of the esophageal epithelium, neck region of the gastric glands, lower half of the intestinal villi, and lower one-third of the colonic crypts. Compound X-induced nuclear pleomorphism was observed in the basal part of the stratified epithelium of the anterior stomach, above the boundary of the crypts in the jejunum and ileum, matching the proliferative zone. This pleomorphism may disrupt the normal differentiation process of the intestinal epithelium, inhibiting regeneration and the subsequent loss of mature mucosal cells.

The following table summarizes the observed effects of Compound X on various tissue types and their proliferative status:

In the testes, Compound X induced necrosis in metaphase spermatocytes at stage XII and karyomegaly in spermatogonia at stages I–VI. Unlike many anticancer drugs, such as cyclophosphamide, bleomycin, and adriamycin, which mainly target spermatogonia, Compound X appears to affect both spermatogonia and differentiating spermatocytes, potentially inhibiting spermatogenesis. The present results indicate that Compound X induced multinucleation through broader multikinase inhibition. This multinucleation-inducing effect, in vivo, targeted highly proliferative cells and zones in the whole body, as well as some mature hematolymphoid cells. This multinucleation may result in cell death, providing a mechanistic basis for selective cytotoxicity in cancer cells.

In general, inhibitors that perturb cell cycle progression and mitotic processes can affect not only tumor cells but also normal tissues with high proliferative activity. Consistent with this concept, the bone marrow, hematological, and gastrointestinal toxicities observed in this study may reflect on-target pharmacological effects on proliferative compartments. Future research is expected to contribute to a more detailed understanding of the multinucleation-induction mechanism through detailed in vivo analyses and clinical trials, leading to the development of new treatments, such as anticancer drugs.

Authors: ET wrote the original manuscript. ET, KT, HH, TA, MK, KN, GY, RY, YM, TM, and YM reviewed and edited the manuscript. ET, KT, HH, TA, MK, KN, GY, RY, and TM conducted the investigation. YM and TM supervised the work. All authors reviewed the manuscript. The authors are employees of Toray Industries, Inc. and Kamakura Techno-Science, Inc.